- Home
- BANX vs PBYI Comparison
BANX vs PBYI Comparison
Compare BANX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANX
- PBYI
- Stock Information
- Founded
- BANX 2013
- PBYI 2010
- Country
- BANX United States
- PBYI United States
- Employees
- BANX N/A
- PBYI N/A
- Industry
- BANX Trusts Except Educational Religious and Charitable
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- BANX Finance
- PBYI Health Care
- Exchange
- BANX Nasdaq
- PBYI Nasdaq
- Market Cap
- BANX 143.2M
- PBYI 138.4M
- IPO Year
- BANX N/A
- PBYI N/A
- Fundamental
- Price
- BANX $19.96
- PBYI $2.91
- Analyst Decision
- BANX
- PBYI Strong Buy
- Analyst Count
- BANX 0
- PBYI 1
- Target Price
- BANX N/A
- PBYI $7.00
- AVG Volume (30 Days)
- BANX 16.4K
- PBYI 280.0K
- Earning Date
- BANX 06-13-2025
- PBYI 05-08-2025
- Dividend Yield
- BANX 10.49%
- PBYI N/A
- EPS Growth
- BANX N/A
- PBYI 143.51
- EPS
- BANX 2.35
- PBYI 0.77
- Revenue
- BANX $29,467,794.00
- PBYI $232,668,000.00
- Revenue This Year
- BANX N/A
- PBYI N/A
- Revenue Next Year
- BANX N/A
- PBYI N/A
- P/E Ratio
- BANX $8.61
- PBYI $3.78
- Revenue Growth
- BANX 2.73
- PBYI 2.67
- 52 Week Low
- BANX $17.91
- PBYI $2.23
- 52 Week High
- BANX $21.67
- PBYI $5.20
- Technical
- Relative Strength Index (RSI)
- BANX 47.62
- PBYI 44.50
- Support Level
- BANX $19.93
- PBYI $2.88
- Resistance Level
- BANX $20.28
- PBYI $3.14
- Average True Range (ATR)
- BANX 0.42
- PBYI 0.16
- MACD
- BANX 0.04
- PBYI 0.00
- Stochastic Oscillator
- BANX 26.00
- PBYI 11.36
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds, and others.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.